SLC5A2 and type 2 diabetes mellitus: According to the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) study, treatment with one of the SGLT-2 inhibitors, empagliflozin, decreased the rate of cardiovascular death and hospitalization for HF in diabetic patients [12].